procarbazine + prednisone + gemcitabine + etoposide

This is a combination chemotherapy regimen consisting of four drugs—procarbazine, prednisone, gemcitabine, and etoposide. Each component has a distinct mechanism of action: - Procarbazine is an alkylating agent that inhibits DNA, RNA, and protein synthesis. - Prednisone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. - Gemcitabine is an antimetabolite nucleoside analog that inhibits DNA synthesis by incorporation into DNA strands during replication. - Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks by preventing the re-ligation of double-stranded breaks induced by the enzyme. This specific four-drug combination does not correspond to any widely recognized or standard named regimen in current clinical practice or literature. However, similar regimens using subsets of these drugs (such as BEACOPP or PEP-C) are used for treating various lymphomas[1][3][4][5]. The rationale for combining these agents would be to leverage their complementary mechanisms for enhanced cytotoxicity against malignant cells.